Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region

Mise à jour : Il y a 4 ans
Référence : NCT00600782

Femme et Homme

Extrait

This study will assess the safety and immunogenicity of a GSK Biologicals' candidate TB vaccine administered at 0, 1 months to healthy adults living in a TB-endemic region. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Critère d'inclusion

  • Tuberculosis (TB)

Liens